• The FDA will not meet PDUFA goal dates for Pfizer Inc's (NYSE: PFE) marketing application for abrocitinib for severe atopic dermatitis and the supplemental application for Xeljanz/Xeljanz XR (tofacitinib) for active ankylosing spondylitis.

• The FDA cited its ongoing review of Pfizer's post-marketing safety study, ORAL Surveillance, evaluating tofacitinib in rheumatoid arthritis patients as a factor for the extensions.

• As communicated in April, the FDA had previously extended the PDUFA goal dates to early Q3 2021. ​

• Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK).

• Xeljanz (tofacitinib) is approved in the U.S. in four indications.

• Price Action: PFE shares are up 0.05% at $41.04 during the premarket session on the last check Thursday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• Johnson & Johnson's COVID-19 Shot Is Less Effective Against Delta Variant: Study

• Pfizer/BioNTech Strike COVID-19 Manufacturing Deal With Biovac For South Africa

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.